Lytix Biopharma is conducting a phase I/II study with three study arms - a phase I/II, open-label, multi-arm, multi-centre, multi-dose, dose escalation study with expansion cohorts of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumours:
• ALL SOLID TUMOURS – LTX-315 as monotherapy • MALIGNANT MELANOMA – LTX-315 in combination with ipilimumab • BREAST CANCER – LTX-315 in combination with pembrolizumab in patients with triple negative breast cancer
The study is ongoing and if you want to learn more about who can participate, please contact us at email@example.com for more information.
ALL SOLID TUMOURS – patient inclusion ongoing
Patients with advanced cancer and at least one lesion accessible for direct transdermal injection.
MALIGNANT MELANOMA – patient inclusion ongoing
Patients with a confirmed diagnosis of unresectable/metastatic melanoma and at least one lesion accessible for intratumoural injection. All patients must have received prior anti-PD-1 treatment as monotherapy or as part of combination for unresectable/metastatic melanoma.
BREAST CANCER, TRIPLE NEGATIVE – patient inclusion completed
Patients with unresectable/metastatic triple negative breast cancer (TNBC) and at least one lesion accessible for transdermal intratumoural injection. All patients must have received 1-4 prior treatment(s) for unresectable/metastatic TNBC and be anti-PD-1 treatment naive.
The LTX-315 study is being carried out at several sites in Norway and other European countries. Study investigators are recruiting patients and welcome enquiries from potential participants. Details about the trial are available at www.clinicaltrials.gov.
Contact information and some facts about our study (all in Norwegian) can be found here.